Stocks in play: Novamind Inc.
Announced it has been selected by Mind Medicine, Inc to host a phase IIb randomized clinical trial investigating lysergic acid diethylamide (LSD) for generalized anxiety disorder in adults. MindMed is a clinical-stage biotech company developing the next generation of psychedelic-inspired medicines and therapies. The LSD Clinical Trial is the most advanced program in MindMed's clinical drug development pipeline and is the first commercial study of LSD in over 40 years. Novamind Inc. shares C.NM are trading down one cent at $0.28.
Read:
Reducing the Risks of Adverse Reactions to Covid Vaccines May Also Reduce Hesitancy and Injuries
Growing Plant-Based Protein Wholesalers Seizing Upon Market’s Appetite for Vegan Options
Therapy Shake-Up Called for by Mental Health Experts Seeking Solutions for Mental Health Crisis
Pharmacies and In-Clinic Testing Set to Remain as Covid-19 Numbers Shift into Post-Pandemic Phase
Biotech Innovators Making Strides Towards Meeting Increased Demand for Breast Cancer Treatments